Cohance Lifesciences Ltd (COHANCE) share price, results

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	231	220	253	488	604	676	840	549	556	545	619	422
Expenses	133	154	180	363	398	439	611	437	435	449	520	421
Operating Profit	98	66	73	125	205	237	229	112	121	95	99	1
OPM %	42%	30%	29%	26%	34%	35%	27%	20%	22%	18%	16%	0.3%
Other Income	20	14	17	19	16	22	-4	6	16	1	-18	12
Interest	0	2	2	10	10	11	10	10	9	9	9	7
Depreciation	12	13	17	31	38	44	54	45	44	47	51	50
Profit before tax	105	65	71	103	174	205	161	63	84	41	20	-43
Tax %	25%	29%	25%	27%	21%	25%	27%	26%	21%	29%	58%	5%
Net Profit	80	47	53	75	138	153	117	46	66	29	8	-45
EPS in Rs	3.13	1.84	2.10	2.96	5.44	6.01	4.73	1.28	1.94	0.96	0.51	-0.63

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	378	834	1,010	1,320	1,340	1,051	2,608	2,269	2,142
Expenses	206	449	567	738	766	645	1,811	1,841	1,825
Operating Profit	172	385	443	582	574	406	797	427	316
OPM %	45%	46%	44%	44%	43%	39%	31%	19%	15%
Other Income	1	66	68	133	46	62	53	4	11
Interest	3	23	12	9	13	7	41	37	34
Depreciation	12	24	32	39	48	55	167	187	192
Profit before tax	158	405	468	668	560	406	643	207	101
Tax %	31%	22%	23%	32%	27%	26%	25%	27%
Net Profit	109	317	362	454	411	300	484	150	59
EPS in Rs		12.45	14.23	17.83	16.16	11.80	19.14	4.68	2.78
Dividend Payout %	0%	20%	14%	28%	37%	0%	0%	0%

	10 Years	5 Years	3 Years	TTM	1 Year	Last Year
Compounded Sales Growth	%	18%	19%	-20%
Compounded Profit Growth	%	-12%	-23%	-77%
Stock Price CAGR	%	-3%	-7%		-48%
Return on Equity	%	15%	11%			5%

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	0.00	13	25	25	25	25	25	38
Reserves	578	832	1,155	1,502	1,710	2,025	3,623	3,873
Borrowings	83	186	143	97	70	65	486	400
Other Liabilities	123	142	151	205	160	138	1,346	1,415
Total Liabilities	783	1,173	1,474	1,830	1,966	2,254	5,480	5,727
Fixed Assets	271	357	441	534	663	670	3,107	3,369
CWIP	111	102	96	30	165	179	334	178
Investments	7	338	542	598	536	904	337	529
Other Assets	394	376	395	667	601	501	1,702	1,652
Total Assets	783	1,173	1,474	1,830	1,966	2,254	5,480	5,727

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	50	407	383	330	457	358	673	368
Cash from Investing Activity	-65	-413	-311	-136	-195	-362	-388	-251
Cash from Financing Activity	26	7	-76	-156	-242	-14	-327	-165
Net Cash Flow	11	1	-5	37	20	-18	-42	-48
Free Cash Flow	-6	304	272	255	171	307	357	169
CFO/OP	49%	128%	111%	88%	105%	115%	107%	102%

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	142	51	37	65	30	46	108	110
Inventory Days	556	278	243	259	279	268	209	310
Days Payable	190	113	100	97	63	49	120	157
Cash Conversion Cycle	509	217	180	228	247	265	197	263
Working Capital Days	205	64	56	108	99	115	106	133
ROCE %		50%	40%	41%	32%	19%	21%	6%

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	60.00%	60.00%	50.10%	50.10%	50.10%	50.10%	50.10%	66.41%	57.49%	57.49%	57.49%	57.49%
FIIs	10.01%	10.14%	9.54%	9.80%	10.70%	10.84%	11.05%	7.23%	6.51%	6.01%	5.59%	6.50%
DIIs	14.13%	15.94%	17.24%	17.42%	16.95%	16.67%	16.60%	11.40%	20.81%	21.57%	21.79%	20.09%
Government	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	15.85%	13.93%	23.11%	22.67%	22.26%	22.37%	22.24%	14.95%	15.16%	14.91%	15.11%	15.92%
No. of Shareholders	73,715	70,052	68,932	65,777	69,337	84,210	86,325	80,910	75,284	81,877	85,230	99,149

Fundamentals

Market Cap₹ 17,519 Cr.

Current Price₹ 458

Stock P/E163

Book Value₹ 102

ROCE5.81 %

ROE4.89 %

Dividend Yield0.00 %

Face Value₹ 1.00

Compounded Sales Growth (TTM)-20%

Compounded Profit Growth (TTM)-77%

Consolidated figures.

Valuation

Market capRs 11,489 Cr

Enterprise valueRs 11,503 Cr

P/E (TTM)108.15x

Price to book5.60x

Price to sales5.36x

EV / EBITDA35.18x

EV / EBIT85.08x

EV / sales5.37x

Price to cash flow32.05x

Earnings yield0.92%

P/E, 3-year average40.44x

P/B, 3-year average8.55x

P/E, 5-year average32.05x

P/B, 5-year average7.57x

Profitability

Operating margin (excl. other income)38.61%

Operating margin (incl. other income)44.49%

EBITDA margin15.27%

Pre-tax margin4.74%

Net profit margin4.96%

Net margin, latest quarter-5.71%

ROE15.86%

ROCE21.07%

ROA14.23%

ROE, 3-year average24.86%

ROCE, 3-year average33.44%

ROA, 3-year average21.12%

ROE, 5-year average30.99%

ROCE, 5-year average38.32%

ROA, 5-year average24.63%

ROIC (approx.)4.85%

Tax rate25.98%

Other income / net worth3.02%

Growth

Sales growth (latest year)-21.56%

Profit growth (latest year)-26.99%

Sales CAGR, 3 years1.36%

Sales CAGR, 5 years22.71%

Profit CAGR, 3 years-6.07%

Profit CAGR, 5 years22.41%

Sales growth QoQ-31.80%

Profit growth QoQ-223.38%

Sales growth YoY (latest quarter)-23.13%

Profit growth YoY (latest quarter)-149.35%

Per share

EPS (TTM)Rs 4.17

EPS (latest year)Rs 11.80

EPS (latest quarter)Rs -0.95

EPS, 3-year averageRs 15.26

EPS, 5-year averageRs 16.98

Book value per shareRs 80.56

Sales per shareRs 84.12

Cash flow per shareRs 14.08

Free cash flow per shareRs 6.64

Dividend per share, 3-year averageRs 5.50

Dividend per share, 5-year averageRs 4.50

Dividends

Dividend payout, 3-year average32.60%

Dividend payout, 5-year average24.83%

Efficiency

Asset turnover0.47x

Fixed asset turnover1.57x

Inventory turnover1.95x

Inventory days187 days

Debtor days46 days

Debtors turnover7.87x

Creditor days157 days

Cash conversion cycle263 days

Working capital days133 days

Leverage

Total debtRs 65 Cr

Cash and bankRs 50 Cr

Net debtRs 14 Cr

Debt to equity0.03x

Net debt / EBITDA0.04x

Interest coverage4.00x

Current ratio (filing 2026-03-31)2.78x

Quick ratio (filing 2026-03-31)1.91x

Trade payables (filing 2026-03-31)Rs 285 Cr

Owners' fund to total sources90.98%

Debt to assets2.88%

Cash flow

Cash from Operating Activity (latest year)Rs 358 Cr

Cash from Investing Activity (latest year)Rs -362 Cr

Cash from Financing Activity (latest year)Rs -14 Cr

Net Cash Flow (latest year)Rs -18 Cr

Free cash flow (latest year)Rs 169 Cr

FCFE (approx.: FCF + change in debt)Rs 164 Cr

Cash from ops / profit, 5 years1.22x

Sales to cash flow2.93x

Statement figures

Net sales (TTM)Rs 2,142 Cr

Net sales (latest year)Rs 1,051 Cr

Sales (latest quarter)Rs 422 Cr

Operating profit excl. other income (latest year)Rs 406 Cr

Operating profit (latest quarter)Rs 1 Cr

Other income (TTM)Rs 11 Cr

EBITDA (TTM)Rs 327 Cr

PBDT (TTM)Rs 293 Cr

Profit before tax (TTM)Rs 101 Cr

Tax (latest year)Rs 105 Cr

Net profit (TTM)Rs 106 Cr

Net profit (latest year)Rs 300 Cr

Net profit (latest quarter)Rs -24 Cr

Depreciation (TTM)Rs 192 Cr

Depreciation (latest quarter)Rs 50 Cr

Interest (TTM)Rs 34 Cr

Cost of goods sold (latest year)Rs 450 Cr

Total expenditure (latest year)Rs 645 Cr

Total income (latest year)Rs 1,113 Cr

Share capitalRs 25 Cr

ReservesRs 2,025 Cr

Shareholders' fundsRs 2,051 Cr

Total assetsRs 2,254 Cr

Net blockRs 670 Cr

Capital work in progressRs 179 Cr

InvestmentsRs 904 Cr

ReceivablesRs 134 Cr

InventoryRs 231 Cr

Other liabilitiesRs 138 Cr

Shares outstanding (crore)25.46

Ownership

Promoter holding57.49% (-8.92 in a year)

Computed by MarketFriction from the consolidated statements. Returns use average balances.

P/E 108.2 is at the 78th percentile of its own 5.4-year range (median 48.6, low 24.5, high 144.1).

P/B 5.60 is at the 8th percentile (median 14.37).

Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.

Period	COHANCE	Nifty 50	Difference
1 week	-0.6%	-2.8%	+2.2 pts
1 month	-1.9%	-6.8%	+4.9 pts
3 months	-0.7%	-7.6%	+6.9 pts
6 months	+49.7%	+0.4%	+49.3 pts
1 year	-49.8%	-9.9%	-39.9 pts
2 years	-63.9%	-13.6%	-50.3 pts
3 years	-19.6%	+14.2%	-33.8 pts
5 years	-14.3%	+27.9%	-42.2 pts

99 mutual fund schemes hold about ₹3,025 Cr. Over three months 13 bought more and 33 sold (share counts, price move removed).

Fund	Weight	Est. Cr	3m shares
ICICI Pru Healthcare Fund-	4.08%	286	-5%
SBI Multi Asset Allocation Fund(A	1.13%	237	-7%
Invesco India Contra Fund	0.97%	200	+7%
HDFC Balanced Advantage Fund	0.18%	189	+0%
DSP Healthcare Fund	3.81%	146	-7%
Bandhan Small Cap Fund	0.41%	141	-5%
SBI Balanced Advantage Fund	0.33%	138	+0%
DSP Aggressive Hybrid Fund	0.91%	107	-15%
SBI MNC Fund	1.49%	100	-6%
SBI Healthcare Opp Fund	1.73%	100	-13%
ICICI Pru Aggressive Hybrid Fund(A	0.19%	99	-5%
DSP Large & Mid Cap Fund	0.51%	94	-27%
ICICI Pru Innovation Fund	1.19%	93	-4%
DSP Flexi Cap Fund	0.72%	90	-21%
ICICI Pru India Opp Fund	0.22%	85	-24%
Invesco India Focused Fund	1.25%	80	-11%
ICICI Pru Value Fund	0.13%	80	-23%
ICICI Pru Multi Cap Fund	0.38%	75	+100%
ICICI Pru Multi Cap Fund	0.38%	72	+100%
HDFC ELSS-Tax Saver Fund	0.41%	65	-1%
HDFC Large & Mid Cap Fund	0.19%	58	-3%
HDFC Manufacturing Fund	0.38%	40	-3%
UTI Healthcare Fund	2.21%	32	-9%
Aditya Birla SL Large & Mid Cap Fund	0.53%	32	-3%
DSP Multi Cap Fund	1.04%	32	-3%

Red flags

F-score 5 of 8

explain

Receivables outrunning sales Receivables grew 20% vs sales -22% in 2026

Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026

Sales ₹422 Cr -23.1% vs Jun 2025. Net loss ₹45 Cr.

Against our estimate for Jun 2026: sales -0.4%, profit -255.1% miss. Our estimate for Sep 2026: sales Rs 419 Cr, profit Rs 14 Cr (how).

Activity

Compare

Company	Mcap (Cr)	P/E	ROCE
Sun Pharmaceutical Industries Ltd	447,476	35.4	20.5 %
Divis Laboratories Ltd	250,363	84.0	22.0 %
Torrent Pharmaceuticals Ltd	186,152	83.4	15.2 %
Zydus Lifesciences Ltd	119,750	24.6	21.1 %
Cipla Ltd	111,430	31.1	15.5 %
Laurus Labs Ltd	106,928	97.8	17.8 %
Mankind Pharma Ltd	105,120	49.3	13.5 %
Dr Reddys Laboratories Ltd	104,494	32.4	13.0 %
Aurobindo Pharma Ltd	97,682	25.8	12.9 %
Lupin Ltd	93,840	15.8	29.9 %
Glenmark Pharmaceuticals Ltd	68,905	22.1	39.8 %
Alkem Laboratories Ltd	62,772	27.6	21.2 %
Biocon Ltd	61,439	84.5	3.61 %
Abbott India Ltd	57,949	35.9	44.8 %
Gland Pharma Ltd	49,333	43.1	15.1 %

No bulk or block deals on record.

Ex-date	Action	Factor
2024-08-06	Annual General Meeting
2023-12-12	Annual General Meeting
2022-09-09	Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per Share
2022-08-11	Annual General Meeting
2022-05-13	Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per Share
2022-02-15	Interim Dividend - Re 1 Per Share/ Special Dividend - Rs 2 Per Share
2021-08-13	Annual General Meeting/Dividend - Re 1 Per Share
2021-02-17	Interim Dividend - Re 1 Per Share
2020-09-25	Bonus 1:1	0.5000

Date	Type	What it says
2026-09-21	Updates	Completion of USFDA Inspection.
2026-09-18	General Updates	General Updates
2026-09-17	Shareholder meeting	Proceedings of Annual General Meeting held on September 17, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along w...
2026-09-17	Concall / analyst meet	Schedule of Analysts/ Institutional Investors Meet
2026-09-05	General Updates	Completion of USFDA Inspection
2026-09-03	Press Release	A press release dated September 03, 2026, titled "Press Release ".
2026-09-03	Committee Meeting Updates	Outcome of Committee Meeting held on September 03, 2026.
2026-08-27	Concall / analyst meet	Schedule of meet
2026-08-26	General Updates	Submission of BRSR
2026-08-26	General Updates	Integrated Annual Report 2026
2026-08-26	Shareholder meeting	Notice of Annual General Meeting to be held on 17 September 2026
2026-08-13	Credit Rating- Others	Credit Rating- Others
2026-08-11	Concall / analyst meet	Transcript
2026-08-05	Concall / analyst meet	Link of Recording
2026-08-05	General Updates	Completion of USFDA Inspection
2026-08-05	Investor Presentation	Investor Presentation
2026-08-05	Press Release	A press release dated August 05, 2026, titled "Press Release".
2026-08-05	Board meeting outcome	Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-23	General Updates	Allotment of Equity Shares pursuant to exercise of Stock Options and grant of Stock Options to certain eligible employees of the Company
2026-07-23	Concall / analyst meet	Schedule of meet
2026-07-20	Reply to Clarification- Fina	The Exchange had sought clarification from Cohance Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (L...
2026-06-30	Disclosure under SEBI Takeov	Jusmiral Holdings Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Sub...
2026-06-23	Disclosure under SEBI Takeov	Berhyanda Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial...
2026-06-18	Resignation	Resignation of Director/KMP/SMP
2026-06-17	Resignation	Resignation of Himanshu Agarwal as Executive Director and Chief Financial Officer of the company w.e.f. September 13, 2026.

Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.

No short selling reported to NSE in our files.

Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.

High low price variation greater than 150perc in previous 12 monthsHigh low price variation greater than 200perc in previous 365 DaysScrip PE is greater than 50 (4 trailing quarters)The Overall encumbered share in the scrip is more than 50 Percent.

Quick answers

What is the market cap of Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd (COHANCE) has a market capitalisation of Rs 17,519 Cr. at the 2026-10-01 close.

What is the P/E ratio of Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd trades at a P/E of 163 on trailing twelve-month profit, at the 2026-10-01 close.

What were Cohance Lifesciences Ltd's latest quarterly results?

In the Jun 2026 quarter, Cohance Lifesciences Ltd sales was Rs 422 Cr (-23.1% vs Jun 2025) with a net loss of Rs 45 Cr.

What is the 52-week high and low of Cohance Lifesciences Ltd?

The 52-week high is Rs 917.85 and the 52-week low is Rs 266.70.